Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?

被引：1
|
作者：
Wang, Victoria E. [1 ,2 ,4 ]
Gainor, Justin F. [3 ]
机构：
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[2] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA USA
[3] Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[4] 1825 Fourth St, Sixth Floor, San Francisco, CA 94158 USA
来源：
JAMA ONCOLOGY | 2024年 / 10卷 / 01期
关键词：
AFATINIB;
D O I：
10.1001/jamaoncol.2023.5004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：52 / 53
页数：2
相关论文
共 50 条
  • [41] Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
    Leah Wells
    Angel Qin
    Current Treatment Options in Oncology, 2023, 24 : 1802 - 1814
  • [42] EGFR mutations in non-small cell lung cancer - Clinical implications
    Charpidou, Andriani
    Blatza, Despoina
    Anagnostou, Elsa
    Syrigos, Konstantinos N.
    IN VIVO, 2008, 22 (04): : 529 - 536
  • [43] Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
    Wells, Leah
    Qin, Angel
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) : 1978 - 1993
  • [44] Impact of EGFR mutations on treatment of non-small cell lung cancer
    Bruce E. Johnson
    David Jackman
    Pasi A. Jänne
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 5 - 9
  • [45] Impact of EGFR mutations on treatment of non-small cell lung cancer
    Johnson, Bruce E.
    Jackman, David
    Janne, Pasi A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (Suppl 1) : S5 - S9
  • [46] Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR)
    Khan, Tahsin M.
    Verbus, Emily A.
    Gandhi, Saumil
    Heymach, John V.
    Hernandez, Jonathan M.
    Elamin, Yasir Y.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (08) : 4688 - 4689
  • [47] Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice
    Yamada, Yutaka
    Tamura, Tomohiro
    Yamamoto, Yusuke
    Ichimura, Hideo
    Hayashihara, Kenji
    Saito, Takefumi
    Yamada, Hideyasu
    Endo, Takeo
    Nakamura, Ryota
    Inage, Yoshihisa
    Satoh, Hiroaki
    Iguchi, Kesato
    Saito, Kazuto
    Inagaki, Masaharu
    Kikuchi, Norihiro
    Kurishima, Koichi
    Ishikawa, Hiroichi
    Sakai, Mitsuaki
    Kamiyama, Koichi
    Shiozawa, Toshihiro
    Hizawa, Nobuyuki
    Sekine, Ikuo
    Sato, Yukio
    Funayama, Yasunori
    Miyazaki, Kunihiko
    Kodama, Takahide
    Hayashi, Shigen
    Nomura, Akihiro
    Nakamura, Hiroyuki
    Furukawa, Kinya
    Yamashita, Takaaki
    Okubo, Hatsumi
    Suzuki, Hisashi
    Kiyoshima, Moriyuki
    Kaburagi, Takayuki
    ANTICANCER RESEARCH, 2020, 40 (10) : 5757 - 5764
  • [48] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Xiuning Le
    Eric Nadler
    Daniel B. Costa
    John Victor Heymach
    Targeted Oncology, 2023, 18 : 807 - 817
  • [49] Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
    Attili, Ilaria
    Passaro, Antonio
    Pisapia, Pasquale
    Malapelle, Umberto
    de Marinis, Filippo
    CURRENT ONCOLOGY, 2022, 29 (01) : 255 - 266
  • [50] Uncommon EGFR Mutations in Non-Small Cell Lung Cancer: A Systematic Literature Review of Prevalence and Clinical Outcomes
    John, T.
    Taylor, A.
    Wang, H.
    Cripps, D.
    Eichinger, C.
    Freeman, C.
    Ahn, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S416 - S417
12345